CD8A and cancer: Building on these results, Daillère et al. by performing ex vivo and in vivo experiments recognized that two intestinal oncomicrobiotics (OMBs), named Barnesiella intestinihominis and Enterococcus hirae, orchestrate the anti-cancer therapeutic effects of CTX therapy by increasing the recruitment of IFN-γ-producing γδ T cells and CD8+ effector TILs, and reducing γδ T17 and Treg cells in cancer lesions [16].